Last reviewed · How we verify
Aggrenox
At a glance
| Generic name | Aggrenox |
|---|---|
| Also known as | Dipyridamole plus aspirin |
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Aggrenox To Treat Acute Covid-19 (PHASE3)
- Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients (PHASE4)
- Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients (NA)
- Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) (NA)
- GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients (NA)
- Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (PHASE3)
- Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence (PHASE3)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aggrenox CI brief — competitive landscape report
- Aggrenox updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI